LLLT to Reduce Low Back Pain

Eligibility Criteria

• * Reporting a primary pain point in lower back.
• * Pain intensity reported at baseline must be 4 and above on the Visual Analogue scale (PROMIS Numeric Rating Scale).
• * Individual able to participate fully in all aspects of the study and have understood and signed study informed consent.
• * Have used pain medications or participated in a pain treatment within three days of study enrollment.
• * Have an implanted device (including lap band) in the targeted area of Low Level Laser Treatment.
• * Have used an investigational drug within 30 days of study enrollment.
• * Reports being currently pregnant, lactating, or are of child-bearing potential or are likely to become pregnant during the low level laser treatment phase and are unwilling to use a reliable form of contraception. Acceptable forms of contraception include: Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants; Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm); Intrauterine device (IUD); Total hysterectomy or tubal ligation; Abstinence (no sex).
• * Have a history of any major cardiovascular events including heart valve disease, ongoing angina, cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke, transient ischemic attack, or peripheral vascular disease.
• * Have clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, lymphatic, respiratory, metabolic disease (such as uncontrolled diabetes type 2), active cancer, actively receiving l treatment for cancer or within 1 year of cancer remission.
• * Surgical intervention for pain within 1 month prior to enrollment.
• * Active infection, wound or other external trauma to the areas to be treated with the laser
• * Known photosensitivity disorder.
• * Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.